✦ LIBER ✦

Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial

✍ Scribed by Rini, Brian I.; Quinn, David I.; Baum, Michael; Wood, Laura S.; Tarazi, Jamal; Rosbrook, Brad; Arruda, Lillian Shahied; Cisar, Laura; Roberts, W. Gregory; Kim, Sinil; Motzer, Robert J.

Book ID: 125372446
Publisher: Springer-Verlag
Year: 2014
Tongue: English
Weight: 276 KB
Volume: 10
Category: Article
ISSN: 1776-2596
DOI: 10.1007/s11523-014-0307-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

794 ORAL Randomized Phase III trial of t

794 ORAL Randomized Phase III trial of the multi-kinase inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 141 KB

Phase iii randomized trial of interleuki

Phase iii randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma

✍ Teresa Murray Law; Robert J. Motzer; Madhu Mazumdar; Kenneth W. Sell; Philip Wal 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 723 KB

Background. Treatment with interleukin-2 (IL-2) and lymphokine-activated killer cells (LAK) resulted in responses in some patients with advanced renal cell carcinoma (RCC). However, the relative therapeutic benefit of the addition of LAK to IL-2 was unknown. Methods. A randomized Phase I11 trial wa

O4 Tivozanib hydrochloride versus sorafe

O4 Tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from the Phase III randomized, open-label, multicenter TIVO-1 trial

✍ Motzer, R.; Nosov, D.; Eisen, T.; Lipatov, O.; Tomczak, P.; Lyulko, O.; Harza, M 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 57 KB

Carbonic anhydrase IX as a potential bio

Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET)

✍ Choueiri, Toni K.; Cheng, Suchun; Qu, Angela Q.; Pastorek, Jaromir; Atkins, Mich 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 353 KB

8514 SPECTRUM, a phase III trial for pat

8514 SPECTRUM, a phase III trial for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) receiving chemotherapy with or without panitumumab: interim pooled safety analysis

✍ Stöhlmacher, J.; Davidenko, I.; Winquist, E.; Licitra, L.; Skladowski, K.; Ciule 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 71 KB

Impact of tumor HPV status on outcome in

Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial

✍ Vermorken, J. B.; Psyrri, A.; Mesia, R.; Peyrade, F.; Beier, F.; de Blas, B.; Ce 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 176 KB